Mj. Cullen et al., IMMUNOGOLD LOCALIZATION OF THE 43-KDA DYSTROGLYCAN AT THE PLASMA-MEMBRANE IN CONTROL AND DYSTROPHIC HUMAN MUSCLE, Acta Neuropathologica, 87(4), 1994, pp. 349-354
Immunofluorescence and immunogold labelling were used to localise the
43-kDa dystrophin-associated glycoprotein (43DAG) of the dystrophingly
coprotein complex in control and Duchenne muscular dystrophy (DMD) bio
psies. In control muscle 43DAG was localised by immunofluorescence to
the periphery of the fibre and, by immunogold, was further delimited t
o the plasma membrane. The labelling was indistinguishable from that p
reviously reported for the dystrophin C terminus [5]. Moreover, the di
stance separating adjacent 43DAG labelling sites (120 nm mode) closely
matched that separating dystrophin C-terminal sites. This is strong e
vidence supporting Ervasti & Campbell's model in which the DAG complex
is bound close to the C terminus of dystrophin and in which the DAG c
omplexes are separated by approximately the length of the dystrophin r
od [7, 12]. In DMD, where there is a 80-90 % reduction in the glycopro
tein complex [16], a faint or locally patchy distribution of 43DAG was
seen by immunofluorescence. Measurement of nearest-neighbour distance
s after immunogold labelling showed that in DMD the 43DAG was more dis
persed, which is further evidence that dystrophin is normally involved
in anchoring the DAGs in the plasma membrane. This is significant bec
ause the potential success of dystrophin gene therapy could depend not
only on restoring dystrophin but also on restoring the lost DAGs.